JPRN-C000000275已完成2 期
A phase II study with Tegafur/Uracil and Peg-Interferon after TACE for hepatocelluler carcinoma - A phase II study with Tegafur/Uracil and Peg-Interferon after TACE for hepatocelluler carcinoma
The third department of Internal Medicine, Wakayama Medical University0 个研究点目标入组 20 人开始时间: 2005年11月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Allergic reaction to IFN and/or UFT 2)Positive by prick test of IFN 3)Severe liver damage after TAE 4)Autoimmune disease 5)Depression or mental neuropathic illness 6)Uncontrolled heart or renal desease 7)Pregnant or nursing 8)Extensive leukopenia or extensive thrombocytopia 9)Use Sho-saiko-to 10)Other uncontrolled severe illness 11)Other inappropriate patient
研究者
相似试验
招募中
2 期
Clinical trial on the QOL of the Tegafur/Uracil plus Leucovolin(UFT/LV) to adjuvant chemotherapy for the Stage II, III colorectal cancerresectable StageII, III colorectal cancerJPRN-UMIN000008961Department of Surgery Keio University School of Medicine400
Unknown
2 期
A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)Carcinoma, HepatocellularNCT00384800Far Eastern Memorial Hospital41
已完成
不适用
Phase II study of irinotecan and tegafur gimeracil for NSCLC with EGFR mutation which resistant to EGFR-TKIon-small-cell lung cancerJPRN-UMIN000001800orth Japan Lung Cancer Study Group25
已完成
2 期
UFUR Plus Thalidomide for Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT00519688National Taiwan University Hospital44
尚未招募
不适用
Efficacy of pre operative Tegafur/Uracil and Degarelix combination therapy for high risk prostate cancerprostate cancerJPRN-UMIN000036159Gifu University100